Acrivon Therapeutics
ACRV
63 hedge funds and large institutions have $140M invested in Acrivon Therapeutics in 2024 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 18 increasing their positions, 15 reducing their positions, and 5 closing their positions.
160% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 5
20% more repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 15
15% more funds holding
Funds holding: 55 → 63 (+8)
0.52% more ownership
Funds ownership: 74.18% → 74.71% (+0.52%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
13% less capital invested
Capital invested by funds: $161M → $140M (-$20.8M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$1.15M |
| 2 |
Goldman Sachs
New York
|
+$286K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$248K |
| 4 |
UOC
UBS O'Connor
Chicago,
Illinois
|
+$171K |
| 5 |
PFCS
Pale Fire Capital SE
Prague,
Czech Republic
|
+$111K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Marshall Wace
London,
United Kingdom
|
-$1.54M |
| 2 |
EAM
Exome Asset Management
New York
|
-$817K |
| 3 |
Millennium Management
New York
|
-$278K |
| 4 |
PCM
Prelude Capital Management
New York
|
-$264K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$152K |
ACRV Hedge Fund Activity: Q4 2024 in Review
63 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Acrivon Therapeutics (ACRV) for Q4 2024, worth a combined $140M — down 13% from $161M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new ACRV positions and 5 closed out — a net gain of 8 holders — while 18 added to existing stakes and 15 trimmed.
The largest buyer was BlackRock, adding an estimated $1.15M. The largest seller was Marshall Wace, cutting an estimated $1.54M.
- 63 institutional investors held Acrivon Therapeutics (ACRV) as of Q4 2024, up from 55 in Q3 2024.
- Funds reported $140M of Acrivon Therapeutics stock for Q4 2024, down 13% quarter-over-quarter.
- 13 funds opened new Acrivon Therapeutics positions in Q4 2024 and 5 closed out, a net change of +8 holders.
- The largest Acrivon Therapeutics buyer in Q4 2024 was BlackRock, an estimated $1.15M added.
- The largest Acrivon Therapeutics seller in Q4 2024 was Marshall Wace, an estimated $1.54M sold.
Based on aggregated 13F filings for Q4 2024.